Source-grounded facts extracted from Quince Therapeutics, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Christopher Lowe was appointed as Class III Director at Quince Therapeutics, Inc..
“On February 2, 2022, the Board appointed Mr. Lowe to serve on the Board as a Class III Director, to fill the vacancy resulting from Ms. Lynch’s resignation from the Board.”
Christopher Lowe was appointed as Interim Chief Executive Officer at Quince Therapeutics, Inc..
“On January 28, 2022, the Company appointed Christopher Lowe, the Company’s Chief Operating Officer (“COO”) and Chief Financial Officer (“CFO”), to serve as the Interim Chief Executive Officer (“Interim CEO”) of the Company.”
Stephen S. Dominy resigned as Director at Quince Therapeutics, Inc..
“Ms. Lynch and Dr. Dominy tendered their resignation from the Board, effective as of January 31, 2022.”
Casey C. Lynch resigned as Chairperson of the Board at Quince Therapeutics, Inc..
“Ms. Lynch and Dr. Dominy tendered their resignation from the Board, effective as of January 31, 2022.”
Stephen S. Dominy resigned as Chief Scientific Officer and a member of the Board at Quince Therapeutics, Inc..
“On February 1, 2022, the Company announced the departure of Casey C. Lynch, the Company’s President, Chief Executive Officer and Chairperson of the Board, and Stephen S. Dominy, M.D., the Company’s Chief Scientific Officer and a member of the Board, effective as of January 28, 2022 (the “Departure Date”).”
Casey C. Lynch resigned as President, Chief Executive Officer and Chairperson of the Board at Quince Therapeutics, Inc..
“On February 1, 2022, the Company announced the departure of Casey C. Lynch, the Company’s President, Chief Executive Officer and Chairperson of the Board, and Stephen S. Dominy, M.D., the Company’s Chief Scientific Officer and a member of the Board, effective as of January 28, 2022 (the “Departure Date”).”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.